Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Dennis A. Noe"'
Autor:
Dennis A. Noe
Publikováno v:
Pharmaceutical Statistics. 19:101-112
Various criteria have been proposed for determining the reliability of noncompartmental pharmacokinetic estimates of the terminal disposition phase half-life (t1/2 ) and the extrapolated area under the curve (AUCextrap ). This simulation study assess
Autor:
Dennis A. Noe
Publikováno v:
Pharmaceutical Statistics. 19:88-100
The adjusted r2 algorithm is a popular automated method for selecting the start time of the terminal disposition phase (tz ) when conducting a noncompartmental pharmacokinetic data analysis. Using simulated data, the performance of the algorithm was
Autor:
Dennis A. Noe
Publikováno v:
Clinical Pharmacology in Drug Development. 9
The noncompartmental analysis (NCA) of pharmacokinetic (PK) data is important throughout all phases of clinical drug development. Although there are numerous regulatory guidances and articles in the literature concerned with best practices for the mo
Autor:
Tommy Cedervall, Elizabeth E. Eynon, Xinguo Chen, Sandra L. Wolin, Hong Shi, Derek D. Yang, Dahai Xue, Richard A. Flavell, James D. Smith, Michael Kashgarian, Dennis A. Noe, Douglas E. Brash
Publikováno v:
Proceedings of the National Academy of Sciences. 100:7503-7508
Antibodies against a conserved RNA-binding protein, the Ro 60-kDa autoantigen, occur in 24–60% of all patients with systemic lupus erythematosus. Anti-Ro antibodies are correlated with photosensitivity and cutaneous lesions in these patients and wi
A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer
Autor:
Kathy Elza-Brown, Eric K. Rowinsky, Ross C. Donehower, Dennis A. Noe, Alex A. Adjei, E. Claire Dees, Seamus O’Reilly
Publikováno v:
Investigational New Drugs. 21:75-84
Pyrazoloacridine (PZA, NSC366140, PD115934) is an acridine derivative currently undergoing clinical evaluation. In preclinical testing, PZA has shown selectivity for solid tumor cell lines, activity in hypoxic, noncycling, and multidrug-resistant cel
Publikováno v:
ResearcherID
The U6 small nuclear ribonucleoprotein is a critical component of the eukaryotic spliceosome. The first protein that binds the U6 snRNA is the La protein, an abundant phosphoprotein that binds the 3′ end of many nascent small RNAs. A complex of sev
Autor:
Eric K. Rowinsky, Marna Doucette, Ross C. Donehower, Sharyn D. Baker, Louise B. Grochow, Alex A. Adjei, Tom Spector, Dennis A. Noe, John A. Hohneker, Soo Peang Khor, S E Sartorius
Publikováno v:
Journal of Clinical Oncology. 14:3085-3096
PURPOSE To study the absolute bioavailability and pharmacokinetics of an oral solution of fluorouracil (5-FU) in patients treated with 776C85, an oral inactivator of dihydropyrimidine dehydrogenase (DPD), and to evaluate the feasibility of administer
Autor:
A. Al-Salloum, Pál László, L. Caprino, V. Eclache, G. Togna, O. Fain, M. Graziani, M.H. Aurousseau, S. A. Al-Rasheed, M. Thomas, C. Sorrentino, Dennis A. Noe, A.K. Al-Momen, H.M. Bahakim, M.M. Al-Mugeiren, Abdel Galil M. Abdel Gader
Publikováno v:
Pathophysiology of Haemostasis and Thrombosis. 26:I-V
Autor:
B G Lubejko, Eric K. Rowinsky, Louise B. Grochow, David S. Ettinger, Arlene A. Forastiere, Dennis A. Noe, B Clark, William P. McGuire, S E Sartorius, Mark R. Gilbert
Publikováno v:
Journal of Clinical Oncology. 9:1692-1703
Untreated and minimally pretreated solid tumor patients received alternating sequences of taxol and cisplatin. Sequential dose escalation of each agent using taxol doses of 110 or 135 mg/m2 and cisplatin doses of 50 or 75 mg/m2 resulted in four dosag
Autor:
Dennis A Noe, Karen M Kumor
Publikováno v:
Clinical Pharmacology and Therapeutics. 49:426-432
We developed a pharmacokinetic-pharmacodynamic model of the heart rate response to cocaine consisting of the sum of the baseline heart rate, a chronotropic drug effect, and a conditioned heart rate response. The conditioned response was modeled as ha